Orphazyme A/S
0CUM.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$41
Close$
Share Statistics
| Market cap | $41.00 |
|---|---|
| Enterprise Value | $-70,959.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.74 |
| Beta | 0.21 |
| Outstanding Shares | 42 |
Return
| Return on Equity | -10.23% |
|---|---|
| Return on Assets | -9.88% |
| Return on Invested Capital | -24.62% |
Valuation & Multiples
| P/E Ratio | 20.9 |
|---|---|
| PEG | -11.25 |
| Price to Sales | 0.0 |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | 114.05 |
| Enterprise Value to EBIT | -9.76 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Orphazyme A/S
62 employees
CEO: Mr. Anders Fink Vadsholt M.B.A., M.Sc., MBA Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative rare diseases. The company offers heat stock proteins that focuses on the treatment of neurodegenerative diseases by harnessing the cel...